72 results match your criteria: "Biology and Pathology Center[Affiliation]"
Ann Hematol
November 2024
Hematology Department, Hôpital Pitié Salpêtrière APHP, Sorbonne University, Paris, France.
We present the 6-year update of a phase 2 study evaluating the combination of obinutuzumab and idelalisib in relapse/refractory Waldenstrom macroglobulinemia. The results of the REMODEL trial demonstrated interesting efficacy in a high-risk genotype profile population. The primary endpoint was achieved with a median PFS of 25.
View Article and Find Full Text PDFBlood
August 2024
Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Blood Adv
June 2024
Canther, ONCOLille, INSERM UMR-S1277, CNRS UMR9020, Lille University, Lille, France.
Br J Haematol
June 2024
Haematology Department, APHP, Sorbonne University, University Hospital La Pitié Salpêtrière-Charles Foix, Paris, France.
The bendamustine-rituximab (BR) schedule is an efficient first-line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who received this treatment confirmed a high response rate and good progression-free (PFS) and overall survival (OS). With a median follow-up of 76.
View Article and Find Full Text PDFBlood Adv
October 2023
Department of Genetics and Molecular Pathology, Centre for Cancer Biology, An alliance between SA Pathology and the University of South Australia, Adelaide, Australia.
Semin Hematol
March 2023
Hematology department, Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
Apart from the MYD88 mutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in the diagnosis and treatment tailoring. However, no consensus recommendations are yet available. Consensus Panel 3 (CP3) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the current molecular necessities and best way to access the minimum data required for a correct diagnosis and monitoring.
View Article and Find Full Text PDFJAAD Case Rep
March 2023
Department of Dermatology, Claude Huriez Hospital, CARADERM and University of Lille, U1189 Inserm, Lille, France.
J Mol Diagn
May 2023
Hematology Laboratory, Hospices Civils de Lyon, Pierre-Bénite, France; Team Lymphoma Immuno-Biology, Centre International de Recherche en Infectiologie U1111 INSERM, Lyon, France; University Claude Bernard Lyon I, Lyon, France. Electronic address:
JAAD Case Rep
February 2023
Department of Dermatology, Claude Huriez Hospital, CARADERM and University of Lille, Lille, France.
World J Urol
February 2023
Department of Urology, Hôpital Européen Georges Pompidou, AP-HP.Centre, Université Paris Cité, Paris, France.
Background: Bladder cancer detection and follow-up is based on cystoscopy and/or cytology, but it remains imperfect and invasive. Current research focuses on diagnostic biomarkers that could improve bladder cancer detection and follow-up by discriminating patients at risk of aggressive cancer who need confirmatory TURBT (Transurethral Resection of Bladder Tumour) from patients at no risk of aggressive cancer who could be spared from useless explorations.
Objective: To perform a systematic review of data on the clinical validity and clinical utility of eleven urinary biomarkers (VisioCyt, XpertBladder, BTA stat, BTA TRAK™, NMP22 BC, NMP22 BladderChek Test, ImmunoCyt™/uCyt1+™, UroVysion Bladder Cancer Kit, Cxbladder, ADXBLADDER, Urodiag) for bladder cancer diagnosis and for non-muscle invasive bladder cancer (NMIBC) follow-up.
Genet Med
March 2023
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Purpose: Structural variants (SVs) play an important role in inherited retinal diseases (IRD). Although the identification of SVs significantly improved upon the availability of genome sequencing, it is expected that involvement of SVs in IRDs is higher than anticipated. We revisited short-read genome sequencing data to enhance the identification of gene-disruptive SVs.
View Article and Find Full Text PDFLeukemia
February 2023
Hematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca (IBSAL), CIBERONC and Center for Cancer Research-IBMCC (University of Salamanca-CSIC), Salamanca, Spain.
The diagnosis of Waldenström's macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease presentation. Furthermore, in recent years, WM has witnessed remarkable progress on the diagnostic front, as well as a deeper understanding of the disease biology, which has affected clinical practice. This, together with the increasing variety of tools and techniques available, makes it necessary to have a practical guidance for clinicians to perform the initial evaluation of patients with WM.
View Article and Find Full Text PDFJ Intern Med
January 2023
Endocrinology-Diabetes-Nutrition Department, CHU Montpellier, University of Montpellier, Montpellier, France.
Turk J Anaesthesiol Reanim
June 2022
Division of Geriatrics, Center Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.
Haematologica
November 2021
Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia; School of Medicine, University of Adelaide, Adelaide, SA.
Am J Hematol
September 2021
Laboratoire d'hématologie, Hôpital Avicenne - INSERM U978- Université Paris Sorbonne Nord, Bobigny, France.
Front Immunol
September 2021
UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.
Haematologica
August 2021
Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.
Blood
June 2021
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Conventional therapies for patients with T-cell prolymphocytic leukemia (T-PLL), such as cytotoxic chemotherapy and alemtuzumab, have limited efficacy and considerable toxicity. Several novel agent classes have demonstrated preclinical activity in T-PLL, including inhibitors of the JAK/STAT and T-cell receptor pathways, as well as histone deacetylase (HDAC) inhibitors. Recently, the BCL-2 inhibitor venetoclax also showed some clinical activity in T-PLL.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
March 2021
Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
Context: When an SDHx mutation is identified in a patient with a pheochromocytoma (PCC) or a paraganglioma (PGL), predictive genetic testing can detect mutation carriers that would benefit from screening protocols.
Objective: To define the tumor detection rate in a large cohort of asymptomatic SDHX mutation carriers.
Design And Setting: Retrospective multicentric study in 6 referral centers.
Blood
March 2021
Centre de Recherches en Cancérologie de Toulouse, INSERM UMR-1037, Université de Toulouse III Paul Sabatier, Toulouse, France.
Am J Surg Pathol
February 2021
Departments of Pathology.
FOXL2 somatic mutation occurs in a high percentage of ovarian adult granulosa cell tumors and DICER1 mutations in a high proportion of Sertoli-Leydig cell tumors. These mutations have only been studied in a limited number of juvenile granulosa cell tumors (JGCTs), and their occurrence and frequency in these neoplasms is controversial. We aimed to determine the frequency of FOXL2 and DICER1 mutations in a large cohort of 50 JGCTs, and to evaluate the prognostic impact of these mutations.
View Article and Find Full Text PDFAnn Biol Clin (Paris)
August 2020
CHU Lille, Laboratory of biochemistry, biology and pathology center, Lille, France, University of Lille, Faculty of medicine, Lille, France, Inserm, UMR 1172, JPArc, Faculté de médecine, Université de Lille, France.
Training and education are essential for medical students. During the COVID-19 outbreak, numerous schools and universities have had to close. Ensuring pedagogical continuity requires alternatives to the traditional classroom, especially in medical education.
View Article and Find Full Text PDFJ Med Biochem
January 2020
University of Verona, Section of Clinical Biochemistry, Verona, Italy.
Background: Extreme leukocytosis is known to induce remarkable variations of some clinical chemistry tests, thus leading to possible clinical misinterpretation. This study aimed to define whether also moderate leukocytosis may influence the stability of glucose and blood gases.
Methods: Blood samples are sent to the local laboratory through a pneumatic tube system.
Blood Adv
May 2020
Department of Hematology, Saint-Louis Institute for Research, Université de Paris, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.